Oxipurinol - XORTX Therapeutics
Alternative Names: Oxypurinol - XORTX; XORLO; XRx 101; XRx-008Latest Information Update: 06 Mar 2025
Price :
$50 *
At a glance
- Originator XORTX Pharma
- Developer XORTX Therapeutics
- Class Anti-ischaemics; Antigouts; Antivirals; Pyrazoles; Pyrimidines; Small molecules; Urologics
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II/III Autosomal dominant polycystic kidney disease
- Phase II Acute lung injury
Most Recent Events
- 24 Feb 2025 XORTX Therapeutics intends to request a Type C meeting with the US FDA to discuss its preparedness for submitting a NDA for XORLO™ marketing approval
- 19 Mar 2024 XORTX Therapeutics plans a registrational trial for Autosomal dominant polycystic kidney disease in USA (PO),
- 03 Jan 2024 XORTX Therapeutics files for patent protection for Oxipurinol